[go: up one dir, main page]

AU2002220920A1 - Method for identification of genes involved in specific diseases - Google Patents

Method for identification of genes involved in specific diseases

Info

Publication number
AU2002220920A1
AU2002220920A1 AU2002220920A AU2092002A AU2002220920A1 AU 2002220920 A1 AU2002220920 A1 AU 2002220920A1 AU 2002220920 A AU2002220920 A AU 2002220920A AU 2092002 A AU2092002 A AU 2092002A AU 2002220920 A1 AU2002220920 A1 AU 2002220920A1
Authority
AU
Australia
Prior art keywords
identification
genes involved
specific diseases
diseases
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002220920A
Inventor
Robert Alan Harris
Susan Mary Kingsman
David Krige
Christopher Robert Mundy
William Nigel Rayner
Neil Raymond Ward
Jonathan White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030076A external-priority patent/GB0030076D0/en
Priority claimed from GB0103156A external-priority patent/GB0103156D0/en
Priority claimed from GB0125666A external-priority patent/GB0125666D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of AU2002220920A1 publication Critical patent/AU2002220920A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002220920A 2000-12-08 2001-12-10 Method for identification of genes involved in specific diseases Abandoned AU2002220920A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0030076.4 2000-12-08
GB0030076A GB0030076D0 (en) 2000-12-08 2000-12-08 Analysis method
GB0103156A GB0103156D0 (en) 2001-02-08 2001-02-08 Analysis method
GB0103156.6 2001-02-08
GB0125666A GB0125666D0 (en) 2001-10-25 2001-10-25 Analysis method
GB0125666.8 2001-10-25
PCT/GB2001/005458 WO2002046465A2 (en) 2000-12-08 2001-12-10 Method for identification of genes involved in specific diseases

Publications (1)

Publication Number Publication Date
AU2002220920A1 true AU2002220920A1 (en) 2002-06-18

Family

ID=27255999

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002220920A Abandoned AU2002220920A1 (en) 2000-12-08 2001-12-10 Method for identification of genes involved in specific diseases

Country Status (2)

Country Link
AU (1) AU2002220920A1 (en)
WO (1) WO2002046465A2 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078729A1 (en) 2001-03-29 2002-10-10 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
US20050053940A1 (en) * 2001-11-21 2005-03-10 Joh-E Ikeda Huntington's disease gene transcriptional factors
AU2003223207A1 (en) 2002-03-01 2003-09-16 Exelixis, Inc. SCDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
AU2003255337A1 (en) * 2002-07-31 2004-02-23 Kylix B.V. Use of genes identified to be involved in tumor development for the development of anti-cancer drugs
BR0315411A (en) * 2002-10-18 2005-08-16 Atugen Ag Factor for metastasis and jobs of this
AU2003291136A1 (en) * 2002-11-21 2004-06-18 The General Hospital Corporation Redd1, a transcriptional target of p63 and p53, and methods of use therefor
AU2003297301A1 (en) 2002-11-25 2004-06-18 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Method and apparatus for performing multiple simultaneous manipulations of biomolecules in a two-dimensional array
US20060110393A1 (en) * 2002-12-26 2006-05-25 Eiji Sunahara Novel proteins and use thereof
EP1636588A2 (en) * 2003-06-12 2006-03-22 University of Manitoba Methods for detecting cancer and monitoring cancer progression
SE0302122D0 (en) * 2003-07-22 2003-07-22 Astrazeneca Ab Genetic marker
WO2005059109A2 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Molecular signature of the pten tumor suppressor
EP1712619A4 (en) * 2003-12-24 2008-01-02 Takeda Pharmaceutical SUBSTANCE FOR THE PREVENTION AND TREATMENT OF CANCER
WO2005111239A2 (en) * 2004-04-30 2005-11-24 Decode Genetics Ehf. Haplotypes in the human thioredoxin interacting protein homologue (arrdc3) gene associated with obesity
US20090087423A1 (en) 2004-06-03 2009-04-02 Takeda Pharmaceutical Company Limited Novel protein complex and use thereof
US20080274456A1 (en) * 2004-06-09 2008-11-06 Bruce Yankner Methods and Compositions for Modifying Gene Regulation and Dna Damage in Ageing
EP1791568B1 (en) 2004-08-16 2012-08-15 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801
DOP2007000015A (en) 2006-01-20 2007-08-31 Quark Biotech Inc THERAPEUTIC USES OF RTP801 INHIBITORS
US7825099B2 (en) 2006-01-20 2010-11-02 Quark Pharmaceuticals, Inc. Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
CA2648382C (en) 2006-04-04 2016-10-11 Singulex, Inc. Methods and compositions for highly sensitive analysis of markers and detection of molecules
WO2008054534A2 (en) 2006-05-11 2008-05-08 Quark Pharmaceuticals, Inc. Screening systems utilizing rtp801
WO2007141796A2 (en) 2006-06-09 2007-12-13 Quark Pharmaceuticals, Inc. Therapeutic uses of inhibitors of rtp801l
US8158356B2 (en) 2006-10-16 2012-04-17 Agrigenomics, Inc. Screening for the genetic defect causing tibial hemimelia in bovines
US7872119B2 (en) 2007-02-26 2011-01-18 Quark Pharmaceuticals, Inc. Inhibitors of RTP801 and their use in disease treatment
JP2010520333A (en) 2007-03-01 2010-06-10 セダーズ−シナイ メディカル センター Antioxidant polymer containing [1,2] -dithiolane moiety and use thereof
US8614311B2 (en) 2007-12-12 2013-12-24 Quark Pharmaceuticals, Inc. RTP801L siRNA compounds and methods of use thereof
WO2009086547A1 (en) 2008-01-03 2009-07-09 Cedars-Sinai Medical Center Antioxidant nanosphere comprising [1,2]-dithiolane moieties
US8603531B2 (en) 2008-06-02 2013-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of NSAIDs
EP2370435B1 (en) 2008-11-24 2015-01-07 Cedars-Sinai Medical Center Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
EP2440936A4 (en) 2009-06-08 2013-03-13 Singulex Inc Highly sensitive biomarker panels
US8431346B2 (en) 2009-12-18 2013-04-30 Agrigenomics, Inc. Screening for arthrogryposis multiplex in bovines
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
CA2760873C (en) 2011-12-02 2020-04-21 Sabine Mai Diagnostic methods for hematological disorders
EP3294886A4 (en) 2015-05-11 2019-02-20 Mimetics, LLC Methods for identifying targets for antimicrobial and antiproliferative compounds and compositions therefrom

Also Published As

Publication number Publication date
WO2002046465A3 (en) 2003-11-06
WO2002046465A2 (en) 2002-06-13

Similar Documents

Publication Publication Date Title
AU2002220920A1 (en) Method for identification of genes involved in specific diseases
AU2002306849A1 (en) Identification of essential genes in microorganisms
AU6611900A (en) Techniques for facilitating identification of candidate genes
AU2001279683A1 (en) Biosensor and method for production thereof
AU2002232393A1 (en) Methods for identifying genes associated with diseases or specific phenotypes
AU2745000A (en) Method for nucleic acid isolation and kit
AU2001264134A1 (en) Microconnectors and method for their production
AU2001289827A1 (en) Continuous method of hydrogenation
AU2001268467A1 (en) Identification of genes and compounds for treatment of cancer
AU2001257903A1 (en) Method for treatment of neurodegenerative diseases
AU2002214286A1 (en) Method of profiling protein
AU2002218417A1 (en) Nucleic acid extraction method and kit
AU2002222618A1 (en) Method of analyzing gene expression
AU2002301109A1 (en) Method for the prediction of preeclampsia and other diseases
AU2001287268A1 (en) Method of identifying inhibitors of tie-2
AU2001262152A1 (en) Method for extracting nucleic acids
AU2001269077A1 (en) Methods and means for regulation of gene expression
AU2001247676A1 (en) Methods for in vivo diversification of single genes
AU2002221104A1 (en) Method of detecting relation between genes
AU2001257427A1 (en) Rna metabolism proteins
AU2002221638A1 (en) Method for establishing germ cell-specific gene expression
AU2001293710A1 (en) System and method for operation-integrated user identification
AU2001292468A1 (en) Methods and means of rna analysis
AU2002221076A1 (en) Method of clustering genes
AU2002364153A1 (en) Genetic analysis of gene expression in heterosis